This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Bruce E. Stabile, MD; Thomas J. Howard, MD; Edward Passaro, Jr, MD; Daniel T. O'Connor, MD

Arch Surg. 1990;125(4):451-453.

Abstract
• Chromogranin A (Cg A) is a protein that is coreleased with peptide hormones from gut endocrine cells and tumors. Plasma levels of Cg A, pepsinogen group I, and gastrin were measured in 31 patients with gastrinoma. Mean Cg A level in 10 patients with gastrinoma who were not operated on was 169±32 ng/mL, while in 9 control patients it was 28±5 ng/mL. In 18 patients with gastrinoma with residual tumor after total gastrectomy, the mean Cg A level was 45±6 ng/mL, and in 10 patients with normal gastrin levels after total gastrectomy and tumor excision, the mean Cg A level was 40±4 ng/mL. In 7 patients in whom pregastrectomy and postgastrectomy Cg A levels were measured, the mean reduction was 94 ± 27 ng/mL, or 66%. There was no correlation between Cg A levels and amount of tumor, presence of metastases, or multiple endocrine neoplasia type I syndrome. There was a significant correlation between Cg A and pepsinogen I levels but no correlation between Cg A and gastrin levels. The results suggest that the elevated plasma Cg A levels in patients with gastrinoma are determined primarily by the trophic effects of gastrin on gastric enterochromaffinlike cells rather than by corelease from the gastrin-producing tumor itself.

(Arch Surg. 1990;125:451-453)

Author Affiliations
From the Surgical (Dr Stabile) and Medical (Dr O'Connor) Services, Veterans Administration Medical Center San Diego (Calif); Departments of Surgery (Dr Stabile) and Medicine (Dr O'Connor), University of California San Diego School of Medicine; and the Surgical Service, Veterans Administration Medical Center West Los Angeles (Calif), and Department of Surgery, UCLA School of Medicine (Drs Howard and Passaro).

Footnotes
Accepted for publication August 31, 1989.

Read before the 13th Annual Meeting of the Association of Veterans Administration Surgeons, San Antonio, Tex, May 4, 1989.

Reprint requests to Surgical Service (112), Veterans Administration Medical Center, 3350 La Jolla Village Dr, San Diego, CA 92161 (Dr Stabile).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids
Peracchi et al.
Eur J Endocrinol 2005;152:443-448.
ABSTRACT | FULL TEXT  

The Chromogranin-Secretogranin Family
Taupenot et al.
NEJM 2003;348:1134-1149.
FULL TEXT  

Interaction of Early Growth Response Protein 1 (Egr-1), Specificity Protein 1 (Sp1), and Cyclic Adenosine 3'5'-Monophosphate Response Element Binding Protein (CREB) at a Proximal Response Element Is Critical for Gastrin-Dependent Activation of the Chromogranin A Promoter
Raychowdhury et al.
Mol. Endocrinol. 2002;16:2802-2818.
ABSTRACT | FULL TEXT  

Sp1 and CREB Mediate Gastrin-dependent Regulation of Chromogranin A Promoter Activity in Gastric Carcinoma Cells
Hocker et al.
J. Biol. Chem. 1998;273:34000-34007.
ABSTRACT | FULL TEXT  

Chromogranin A as Serum Marker for Neuroendocrine Neoplasia: Comparison with Neuron-Specific Enolase and the {alpha}-Subunit of Glycoprotein Hormones
Nobels et al.
J. Clin. Endocrinol. Metab. 1997;82:2622-2628.
ABSTRACT | FULL TEXT  

Transcriptional Activation of the Rat Vesicular Monoamine Transporter 2 Promoter in Gastric Epithelial Cells. REGULATION BY GASTRIN
Watson et al.
J. Biol. Chem. 2001;276:7661-7671.
ABSTRACT | FULL TEXT